Inactive Instrument

Pacgen Life Science Corporation

Equities

PBS

CA69374M1041

Biotechnology & Medical Research

Pacgen Life Science Corporation Reports Earnings Results for the First Quarter Ended June 30, 2019

August 29, 2019 at 07:17 pm

Pacgen Life Science Corporation announced earnings results for the first quarter ended June 30, 2019. For the first quarter, the company announced total revenue was CAD 113,378 compared to CAD 122,915 a year ago. Net loss was CAD 84,232 compared to CAD 64,627 a year ago.

Latest news about Pacgen Life Science Corporation

General Biologicals Corporation completed the acquisition of additional 77% stake in Pacgen Life Science Corporation.	29/09/20	CI
Pacgen Life Science Corporation Reports Earnings Results for the First Quarter Ended June 30, 2020	31/08/20	CI
Pacgen Life Science Corporation Reports Earnings Results for the Full Year Ended March 31, 2020	29/07/20	CI
General Biologicals Corporation entered into a letter of intent to acquire additional 77% stake in Pacgen Life Science Corporation for CAD 1.4 million.	06/07/20	CI
Pacgen Life Science Corporation Reports Earnings Results for the Third Quarter Ended December 31, 2019	24/02/20	CI
Pacgen Life Science Corporation Reports Earnings Results for the Second Quarter Ended September 30, 2019	28/11/19	CI
Pacgen Life Science Corporation Reports Earnings Results for the First Quarter Ended June 30, 2019	29/08/19	CI
Pacgen Life Science Corporation Reports Earnings Results for the Full Year Ended March 31, 2019	29/07/19	CI
Pacgen Life Science Corporation Reports Earnings Results for the Third Quarter Ended December 31, 2018	01/03/19	CI
Pacgen Life Science Corporation Announces Management Changes	28/03/18	CI
Pacgen Life Science Corporation Appoints Rakesh Arya as Board of Directors	11/01/18	CI
Pacgen Life Science Corporation announced that it has received CAD 0.74 million in funding	10/01/18	CI
Pacgen Life Science Corporation Gains Exclusive Global Commercial Rights to DermaMed, DermaSoleil and Deserving Health	12/05/17	CI
Pacgen Life Science Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2015	28/02/16	CI
Pacgen Life Science Corporation announced that it has received CAD 0.32 million in funding from Southern Gold Resources Ltd and other investors.	02/02/16	CI
Pacgen Life Sciences Corporation Announces Christina Yip to Board of Directors	19/01/16	CI
Pacgen Life Science Corporation announced that it expects to receive CAD 0.32 million in funding.	18/01/16	CI
Pacgen Life Science Corporation Announces Executive Changes	15/10/15	CI
Pacgen Life Science Corporation Enters Agreement with General Biologicals Corporation	26/01/14	CI
Pacgen Life Science Corporation Announces Executive Changes	29/08/13	CI
Pacgen Life Science Corporation Announces Executive Changes	09/05/13	CI
Pacgen Biopharmaceuticals Corporation will Change its Ticker to PBS from PGA	01/05/12	CI
Pacgen Biopharmaceuticals Corporation has Changed its Name to Pacgen Life Science Corporation	30/04/12	CI
Pacgen Biopharmaceuticals Corporation Appoints Peter Sheu as Chief Operating Officer	06/03/12	CI
Pacgen Biopharmaceuticals Corporation Signs an Amendment to its License Agreement with ACI Global Corporation	30/01/12	CI

Chart Pacgen Life Science Corporation

Duration

Period

More charts

Company Profile

Pacgen Life Science Corporation, formerly Pacgen Biopharmaceuticals Corporation, is a life sciences company focused on the commercialization of life sciences products and services. The Company has a worldwide license to develop and commercialize an antifungal called P113 (also called PAC-113). It has sublicensed its PAC-113 right to General Biologicals Corporation (GBC), which offers non-prescription over-the-counter (OTC) products containing PAC-113 in Taiwan. P113 is a 12 amino-acid antimicrobial peptide derived from a histatin protein found in saliva. Its P113 is used for the treatment of various oral conditions, as well as vaginal, dermatological and ophthalmic conditions. GBC offers products, such as cosmetic skin-care products, oral hygiene products and intimate hygiene products. The oral healthcare product includes Mr.&Mrs.O. It has conducted a Phase IIb dose-ranging clinical trial for PAC-113. Its oral health and woman health products are in the commercialization stage.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B

Other Biotechnology & Medical Research